Evidence map›Paper›PMID 22434068›Full record

ReviewJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism2012

Molecular brain imaging in the multimodality era.

Julie C Price

Open access · bronzeAbstract readReview
In one paragraph

Review in Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Neuroimaging of Parkinson's disease: Expanding views.Neuroscience and biobehavioral reviews · 2015
    Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Julie C PriceDepartment of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA. pricejc@upmc.edu
University of Pittsburgh · US

Funding

Vascular Moderators of the Impact of Alzheimer's Pathology in the Young-OldP01AG025204 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HOWARD J AIZENSTEIN, Ann D. Cohen · 2005 to 2026
$56.5M
TREATMENT OF DEPRESSION IN ALZHEIMER'S DISEASEP50AG005133 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KAMBOH, M. ILYAS · 1985 to 2019
$43.0M
Roles of Gray Matter Brain Aging and Small Vessel Disease in AD PathophysiologyRF1AG025516 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI AIZENSTEIN, HOWARD J, VILLEMAGNE, VICTOR LUIS · 2014 to 2021
$9.0M
AMYLOID PATHOLOGY AND COGNITION IN NORMAL ELDERLYR37AG025516 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KLUNK, WILLIAM E · 2005 to 2014
$4.3M
Amyloid Imaging Agents for Positron Emission TomographyR01AG018402 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MATHIS, CHESTER A · 2001 to 2010
$2.9M
Simple In Vivo PET Measure of Amyloid Binding in ADR01MH070729 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PRICE, JULIE C. · 2004 to 2006
$1.2M
Establishing the In Vivo Threshold for Amyloid Deposition in Normal AgingR01AG033042 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PRICE, JULIE C · 2009 to 2013
$1.2M
Mapping Brain Structure and Function in ADK02AG027998 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PRICE, JULIE C · 2006 to 2010
$520k
PET IMAGING PROBES FOR AMYLOID IN ALZHEIMERS AND AGINGK02AG001039 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KLUNK, WILLIAM E · 2001 to 2005
$488k
Imaging Amyloid Pathology and its Functional SequelaeR21NS060184 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PRICE, JULIE C · 2007 to 2008
$385k
NIA NIH HHS K02 AG001039NIA NIH HHS K02AG001039NIA NIH HHS K02 AG027998NIA NIH HHS K02AG027998NIA NIH HHS P01 AG025204NIA NIH HHS P01AG025204NIA NIH HHS P50 AG005133NIA NIH HHS P50AG005133NIA NIH HHS R01 AG018402NIA NIH HHS R01AG018402NIA NIH HHS R01 AG033042NIA NIH HHS R01AG033042NIA NIH HHS R37 AG025516NIA NIH HHS R37AG025516NIA NIH HHS RF1 AG025516NIMH NIH HHS R01 MH070729NIMH NIH HHS R01MH070729NINDS NIH HHS R21 NS060184NINDS NIH HHS R21NS060184
6 · The paper itself

Abstract

Multimodality molecular brain imaging encompasses in vivo visualization, evaluation, and measurement of cellular/molecular processes. Instrumentation and software developments over the past 30 years have fueled advancements in multimodality imaging platforms that enable acquisition of multiple complementary imaging outcomes by either combined sequential or simultaneous acquisition. This article provides a general overview of multimodality neuroimaging in the context of positron emission tomography as a molecular imaging tool and magnetic resonance imaging as a structural and functional imaging tool. Several image examples are provided and general challenges are discussed to exemplify complementary features of the modalities, as well as important strengths and weaknesses of combined assessments. Alzheimer's disease is highlighted, as this clinical area has been strongly impacted by multimodality neuroimaging findings that have improved understanding of the natural history of disease progression, early disease detection, and informed therapy evaluation.

Indexed as

Alzheimer DiseaseAnimalsBrainHumansMagnetic Resonance ImagingNeuroimagingPositron-Emission Tomography

Identifiers

PMID22434068
PMCPMC3390805
OpenAlexW1994071579

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.